With Sanofi entering the multiple myeloma market, J&J flashes data on new rare disease

In a pivotal Phase III trial presented this weekend at the European Hematology Association virtual meeting, J&J tested three medications often used to treat AL amyloidosis against those three medications plus Darzalex. Although there are no data yet on overall survival, the J&J combo cleared tumors at a far higher clip than the control, which included the multiple myeloma drug Velcade and two chemotherapies.